Marker Therapeutics, Inc. (NASDAQ: MRKR)

Sector: Healthcare Industry: Biotechnology CIK: 0001094038
Market Cap 16.86 Mn
P/B 0.92
P/E -1.18
P/S 3.59
ROIC (Qtr) -102.97
Div Yield % 0.00
Rev 1y % (Qtr) -35.99
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Investment thesis

Bull case

  • Tangible assets of 21.73M provide exceptional 16.06x coverage of deferred revenue 1.35M, showing strong service capability backing.
  • Operating cash flow of (14.82M) fully covers other non-current liabilities (1.35M) by 10.95x, showing strong long-term stability.
  • Tangible assets of 21.73M provide robust 16.06x coverage of other current liabilities 1.35M, indicating strong asset backing.
  • R&D investment of 14.74M represents healthy 10.90x of deferred revenue 1.35M, indicating strong future innovation pipeline.
  • Cash reserves of 18.94M provide robust 5.66x coverage of current liabilities 3.35M, indicating strong short-term solvency.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 14.74M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (14.82M) provides insufficient coverage of deferred revenue obligations of 1.35M, which is -10.95x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (14.82M) shows concerning coverage of stock compensation expenses of 476953, with a -31.07 ratio indicating potential earnings quality issues.
  • Operating cash flow of (14.82M) provides minimal -296.62x coverage of tax expenses of 49953, suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Operating cash flow of (14.82M) barely covers operating expenses of 453135 with a -32.70 ratio, suggesting thin operational efficiency margins and limited flexibility.

Product and Service Breakdown of Revenue (2024)

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.23 11.06
EV to Cash from Ops. EV/CFO -0.34 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -0.35 -13.49
EV to EBITDA EV/EBITDA -0.34 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.34 25.66
EV to Market Cap EV to Market Cap 0.30 203.37
EV to Revenue EV/Rev 1.07 156.31
Price to Book Value [P/B] P/B 0.92 20.59
Price to Earnings [P/E] P/E -1.18 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 110.49 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -47.45 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -45.84 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -46.99 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -46.99 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -11.82 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -72.80 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -12.99 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.22 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 5.66 3.92
Current Ratio Curr Ratio (Qtr) 6.50 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -303.50 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -303.47 -18,246.34
EBT Margin % EBT Margin % (Qtr) -303.47 -19,108.08
Gross Margin % Gross Margin % (Qtr) 100.00 -10.30
Net Profit Margin % Net Margin % (Qtr) -304.50 -19,056.96